Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Details Financial Benefits from Recent Merger, including Improved Balance Sheet and Reduced Debt ServiceJuly 29, 2019

Company to Appeal Nasdaq Staff’s Determination

Emmaus Life Sciences Brings “Sideline Sickle Cell” Campaign to Dallas for Participation in Annual Warriors ConventionJuly 24, 2019

Campaign spokesperson Solomon Wilcots and Senior Vice President of Research and Development for Emmaus, Charles Stark, Pharm.D., will lead an informative presentation at the event’s Young Adult Reception.

Emmaus Life Sciences Receives Notice of Nasdaq Delisting Following Merger with MYnd AnalyticsJuly 22, 2019

Emmaus to Appeal Nasdaq Staff’s Determination

Emmaus Life Sciences Completes MergerJuly 17, 2019

Emmaus Shares Expected to Begin Trading Tomorrow on Nasdaq Under Ticker Symbol “EMMA”

MYnd Analytics and Emmaus Life Sciences Stockholders Approve Merger and Spin-off TransactionsJuly 10, 2019

The proposed merger and spin-off transactions were approved by their respective stockholders at the special stockholder meetings held yesterday, July 9, 2019